1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. DNA/RNA Synthesis

DNA/RNA Synthesis

RNA synthesis, which is also called DNA transcription, is a highly selective process. Transcription by RNA polymerase II extends beyond RNA synthesis, towards a more active role in mRNA maturation, surveillance and export to the cytoplasm.

Single-strand breaks are repaired by DNA ligase using the complementary strand of the double helix as a template, with DNA ligase creating the final phosphodiester bond to fully repair the DNA.DNA ligases discriminate against substrates containing RNA strands or mismatched base pairs at positions near the ends of the nickedDNA. Bleomycin (BLM) exerts its genotoxicity by generating free radicals, whichattack C-4′ in the deoxyribose backbone of DNA, leading to opening of the ribose ring and strand breakage; it is an S-independentradiomimetic agent that causes double-strand breaks in DNA.

First strand cDNA is synthesized using random hexamer primers and M-MuLV Reverse Transcriptase (RNase H). Second strand cDNA synthesis is subsequently performed using DNA Polymerase I and RNase H. The remaining overhangs are converted into blunt ends using exonuclease/polymerase activity. After adenylation of the 3′ ends of DNA fragments, NEBNext Adaptor with hairpin loop structure is ligated to prepare the samples for hybridization. Cell cycle and DNA replication are the top two pathways regulated by BET bromodomain inhibition. Cycloheximide blocks the translation of mRNA to protein.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-160786
    TREX1-IN-3
    Inhibitor
    TREX1-IN-3 (Compound 95) is an inhibitor of both TREX1 and TREX2, with an IC50 for TREX1 of less than 0.1 μM, an IC50 for TREX2 of less than 1 μM, and an EC50 for HCT116 cells of less than 1 μM. TREX1-IN-3 can be used in cancer research.
    TREX1-IN-3
  • HY-145840
    Pol I-IN-1
    Inhibitor
    Pol I-IN-1 is a potent RNA polymerase I (Pol I) inhibitor with IC50 0.21 µM for the Pol I large catalytic subunit RPA194.
    Pol I-IN-1
  • HY-P11685
    Fmoc-PNA-thioU(PMB)-OH
    Fmoc-PNA-thioU(PMB)-OH is a nucleobase-modified peptide nucleic acid (PNA) monomer used in solid-phase synthesis. Fmoc-PNA-thioU(PMB)-OH features a thiouracil base protected with a p-methoxybenzyl (PMB) group on an Fmoc-protected backbone, designed for incorporating modified PNA bases into oligonucleotides to study binding properties.
    Fmoc-PNA-thioU(PMB)-OH
  • HY-150599
    HIV-1 inhibitor-43
    Inhibitor
    HIV-1 inhibitor-43 is a potent HIV-1 inhibitor with an EC50 of 21.3 nM, 6.2 nM, < 0.7 nM and < 0.7 nM for Y188L, K103N-Y181C, K103N and Y181C, respectively. HIV-1 inhibitor-43 can reduce HIV-1 RNA and protein p24 expression.
    HIV-1 inhibitor-43
  • HY-W854187
    2'-Ome-Ac-G Phosporamidite
    2'-Ome-Ac-G (5'-DMT-2'-OMe-rG(N-Ac)) Phosporamiditeyes 2'-Ome-Ac-G (5'-DMT-2'-OMe-rG(N-Ac))Phosphoramidite.
    2'-Ome-Ac-G Phosporamidite
  • HY-P11684
    Fmoc-PNA-C(Boc)-OH
    Fmoc-PNA-C(Boc)-OH is a protected peptide nucleic acid (PNA) monomer for solid-phase synthesis. Fmoc-PNA-C(Boc)-OH possesses Fmoc-protected skeletal amino groups and Boc-protected cytosine bases, designed to construct stable synthetic DNA analogs. Fmoc-PNA-C(Boc)-OH can be used to prepare highly specific, enzyme-stable antisense probes and diagnostic probes.
    Fmoc-PNA-C(Boc)-OH
  • HY-158020
    Anticancer agent 197
    Inhibitor
    Anticancer agent 197 (compound 2b) shows cell cytotoxicity with IC50  values of  10.03 µM and  73.54 µM for HL-60 cells and A549 cells, respectively. Anticancer agent 197 can induce DNA damage.
    Anticancer agent 197
  • HY-W754064
    Cytidine-5'-triphosphate-13C5
    Cytidine-5'-triphosphate-13C5 (Cytidine triphosphate-13C5) is the 13C-labeled Cytidine-5'-triphosphate (HY-125818). Cytidine 5′-triphosphate (Cytidine triphosphate; 5'-CTP) is a nucleoside triphosphate and serves as a building block for nucleotides and nucleic acids, lipid biosynthesis. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate is an essential biomolecule?in the de novo?pyrimidine biosynthetic pathway in?T. gondii.
    Cytidine-5'-triphosphate-<sup>13</sup>C<sub>5</sub>
  • HY-148170
    L-I-OddU
    Inhibitor
    L-I-OddU, a L-5'-halo- dioxolane nucleoside analogue, is a potent and selective anti-Epstein-Barr virus (EBV) agent with an EC50 value of 0.03μM. L-I-OddU has low cytotoxicity with a CC50 value of 1000 nM. L-I-OddU has antiviral activity by suppressing replicative EBV DNA and viral protein synthesis.
    L-I-OddU
  • HY-106015
    Tezacitabine hydrate
    Inhibitor
    Tezacitabine hydrate is a cytostatic and cytotoxic antimetabolite and nucleoside analogue. Tezacitabine hydrate irreversibly inhibits the ribonucleotide reductase and interferes with DNA replication and repair. Tezacitabine hydrate effectively induces cells Apoptosis. Tezacitabine hydrate has the potential for leukemias and solid tumors (carcinomas) treatment.
    Tezacitabine hydrate
  • HY-10246A
    A-837093 sodium
    Inhibitor
    A-837093 sodium is a potent and orally active inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase. A-837093 sodium shows potencies against polymerases derived from both HCV genotypes 1a (IC50 = 1.25 nM) and 1b (IC50 = 0.33 nM). A-837093 sodium exhibits antiviral efficacy in HCV-infected chimpanzees. A-837093 sodium can be used for HCV infection research.
    A-837093 sodium
  • HY-170965
    Anticancer agent 264
    Anticancer agent 264 (Compound 5w) is an anticancer agent that exhibits significant antiproliferative activity across tumor cell lines, with an IC50 range of 7.5-33.67 μM. Anticancer agent 264 significantly induces G2/M phase arrest in MDA-MB-231, MIA PaCa-2, and DU-145 cell lines. Anticancer agent 264 reduces the expression of key cell cycle proteins, including CDK1, CDK2, and Cyclin B1, in a dose-dependent manner, and shows strong binding affinity with inhibitor of differentiation (ID) proteins and DNA-binding proteins. Anticancer agent 264 can be used for research in the field of cancer-related diseases.
    Anticancer agent 264
  • HY-182016
    PROTAC ATR degrader-3
    PROTAC ATR degrader-3 is a potent CRBN-based ATR PROTAC degrader with a DC50 of 127 nM. PROTAC ATR degrader-3 also degrades CHK1 with an DC50 of 135 nM. PROTAC ATR degrader-3 inhibits cancer cells proliferation, migration and invasion, triggers apoptosis and induces S phase arrest and DNA damage. PROTAC ATR degrader-3 achieves tumor growth inhibition in LoVo xenograft mouse model without apparent toxicity. PROTAC ATR degrader-3 can be used for the research of colorectal cancer.
    PROTAC ATR degrader-3
  • HY-112980C
    Nusinersen sodium scrambled negative control
    Nusinersen sodium scrambled negative control is the sequence scrambled negative control of Nusinersen sodium.
    Nusinersen sodium scrambled negative control
  • HY-138593
    5-O-TBDMS-N4-Benzoyl-2-deoxycytidine
    98.00%
    5-O-TBDMS-N4-Benzoyl-2-deoxycytidine is a modified nucleoside. 5-O-TBDMS-N4-Benzoyl-2-deoxycytidine can be used in the synthesis of deoxyribonucleic acid or nucleic acid.
    5-O-TBDMS-N4-Benzoyl-2-deoxycytidine
  • HY-U00279A
    Nitracrine dihydrochloride hydrate
    Inhibitor
    Nitracrine dihydrochloride hydrate inhibits RNA synthesis and covalently, reversibly binds to DNA but also forms covalent adducts with DNA in vivo. Nitracrine dihydrochloride hydrate, a 1-nitroacridine derivative, is a potent hypoxia-selective agent in vitro and antitumor agent. Nitracrine dihydrochloride hydrate has cytotoxicity towards most cells.
    Nitracrine dihydrochloride hydrate
  • HY-183291
    Antibacterial agent 343
    Inhibitor
    Antibacterial agent 343 (Compound 47) is an Antibacterial agent. Antibacterial agent 343 binds to the allosteric site of PBP2a to open its active site. Antibacterial agent 343 disrupts bacterial cell membranes, leading to protein leakage. Antibacterial agent 343 interacts with DNA and inhibits replication and transcription. Antibacterial agent 343 induces ROS accumulation. Antibacterial agent 343 exhibits antibacterial activity against MRSA, Staphylococcus aureus, and Enterococcus faecalis. Antibacterial agent 343 can be used for the research of methicillin-resistant Staphylococcus aureus infections.
    Antibacterial agent 343
  • HY-182936
    Antibacterial agent 338
    Antibacterial agent 338 (Compound 65) is an antibacterial agent and GyrB inhibitor, with an IC50 of 12.60 nM against GyrB from E. coli. Antibacterial agent 338 binds to the ATP-binding domain of E. coli GyrB, thereby inhibiting the ATPase activity of GyrB. Antibacterial agent 338 exhibits broad-spectrum antibacterial activity against multidrug-resistant Gram-negative bacteria. Antibacterial agent 338 reduces bacterial load in a neutropenic mouse thigh infection model. Antibacterial agent 338 can be used for the research of Acinetobacter baumannii infection.
    Antibacterial agent 338
  • HY-W675573
    VF-149
    Inhibitor
    VF-149 is a Ribonucleotide reductase inhibitor. VF-149 significantly inhibits Plasmodium falciparum growth with an IC50 of 6.4  μM. VF-149 has antimalarial and antitumor activities. VF-149 can be used for malarial infections and cancers research.
    VF-149
  • HY-16740
    Eprociclovir
    Inhibitor
    Eprociclovir is an antiviral drug with nucleoside analogues. The triphosphate form of Eprociclovir is converted into the active form within virus-infected cells by the virus and possible cellular enzymes, including the viral thymidine kinase, thereby inhibiting the activity of the viral DNA polymerase. The primary activity of Eprociclovir is against herpes viruses, including but not limited to cytomegalovirus (CMV) and herpes simplex virus (HSV). Eprociclovir can be used in studies interfered with by sensitive viruses.
    Eprociclovir
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.